SS-31
Also known as: Elamipretide, MTP-131
At a Glance
SS-31 (elamipretide, MTP-131) is a mitochondria-targeting peptide investigated in multiple disease contexts where mitochondrial dysfunction is implicated. Randomized clinical trial evidence exists in primary mitochondrial myopathy. [PMID: 37268435]
⚠️ Research Status: SS-31 is not broadly approved across indications. This page is educational and intentionally does not include protocols/dosing.
Mechanism of Action (TBD)
Often described as a mitochondria-targeting peptide interacting with mitochondrial membrane biology (e.g., cardiolipin-associated framing); primary sources should be used for any specific mechanistic claim.
Evidence Summary
Primary mitochondrial myopathy (Randomized clinical trial)
Moderate Confidence RCT ≤3 YearsThe MMPOWER-3 randomized clinical trial reported efficacy and safety outcomes for elamipretide in individuals with primary mitochondrial myopathy. [PMID: 37268435]
Safety & Unknowns
- Indication-specific safety and efficacy depend on the studied population and endpoints.
- Off-context extrapolation (e.g., “energy” or “longevity” claims) is not supported by indication-specific trials.
Regulatory Status
| Region | Status |
|---|---|
| United States (FDA) | Not approved (verify indication-specific context) |
| European Union (EMA) | Not approved (verify indication-specific context) |
| WADA | Check current list (status may change) |
Changelog
| Date | Change |
|---|---|
| 2026-01-23 | Added dossier and linked primary literature |